Alzheimer’s disease (AD) is a devastating neurological disorder that affects more than 37
million people worldwide1. The economic burden of AD is massive; in the United States alone, …

Alzheimer’s disease (AD) is a chronic, progressive, neurodegenerative disorder that places
a substantial burden on patients, their families, and society. The disease affects …

… Alzheimer’s dementia (AD), this review will focus on pharmacological interventions in AD.
Most diseasemodifying therapies … First a short overview on current approved therapies for AD …

Introduction: Nonpharmacological therapies (NPTs) can improve the quality of life (QoL) of
people with Alzheimer’s disease (AD) and their carers. The objective of this study was to …

Alzheimer’s disease (AD) is one of the most common forms of dementia in the elderly.
Currently, there are over 50 million cases of dementia worldwide and it is expected that it will …

Background: Alzheimer’s disease (AD) is the most frequent progressive neurodegenerative
disease. Cholinergic dysfunction is one of the major pathological alteration, although …

Available symptomatic therapies for the treatment of Alzheimer's disease (AD) have been
based on known neurotransmitter dysfunctions associated with the illness. The second-…

… , safety and tolerability of combination therapy in AD, defined as … This review shows that
combination therapy for AD seems to … effectiveness of combination therapy in Alzheimer disease. …

… cognitive measure in clinical trials of Alzheimer’s disease. 5 Research is focused on the
development of therapies to delay or halt the progression of Alzheimer’s disease. However, no …

… Background: The amyloid β (Aβ) peptide is critical to the development of Alzheimer's disease
(AD), the major neurodegenerative disease of the elderly for which there is currently no …